文献速递外周血管介入US

超声引导经皮凝血酶注射治疗非股动脉假性动脉瘤的初步经验与文献回顾

US-guided percutaneous thrombin injection to treat non-femoral artery pseudoaneurysms: preliminary experience and review of the literature.
PubMed 文献 · Radiol Med · 2022-12-16

该回顾性研究纳入2015至2021年接受超声引导经皮凝血酶注射治疗的8例非股动脉假性动脉瘤患者(共16次操作),技术成功率高且无并发症,7/8例(88%)获得临床成功,4例单次治疗成功,3例需多次注射,1例因第二次栓塞失败改行手术缝合。结论认为该方法在选定病例中可行,并发症罕见,多次注射常可达到临床成功。

要点

  • 超声引导凝血酶注射可用于非股动脉假性动脉瘤的择期治疗,临床成功率88%。
  • 多数患者(7/8)瘤颈薄或不可见,操作中需注意瘤颈显示对注射策略的影响。
  • 重复注射不增加并发症风险,是提高临床成功的可行手段。

核心结论

  • 超声引导经皮凝血酶注射治疗非股动脉假性动脉瘤在选定病例中可行,并发症罕见,临床成功常可通过重复注射获得。

研究设计与样本

  • 栓塞指征包括持续抗血小板/抗凝治疗、超声下假性动脉瘤显示清晰或手术风险高;记录病因、位置、大小、瘤颈、并发症、重复治疗次数、临床成功及出院时临床状况。
  • 临床成功终点为术后影像显示假性动脉瘤消失且未转外科手术。

关键影像表现/征象

  • 动脉损伤原因包括导管操作(3例)、中心静脉导管误置(2例)、外伤、出血素质及内支架内漏各1例。
  • 治疗部位包括肱动脉(2例)、锁骨下动脉(2例)、甲状颈干、胫前动脉、桡动脉及胰十二指肠动脉各1例。
  • 假性动脉瘤中位面积为530 mm²(范围32-2400 mm²),瘤颈薄7/8例、不可见1/8例。

诊断标准与关键数值

  • 临床成功定义为术后影像显示假性动脉瘤消失且无需外科手术,本组7/8例(88%)达到临床成功。
  • 单次治疗成功4例,多次治疗成功3例(分别接受4次、3次和2次栓塞)。
  • 1例在第二次经皮栓塞失败后行手术缝合。

临床应用与阅片要点

  • 治疗前应评估假性动脉瘤位置、面积及瘤颈显示情况,瘤颈薄或不可见者仍可尝试超声引导注射。
  • 对于持续抗凝/抗血小板或手术高风险患者,超声引导凝血酶注射可作为替代治疗。
  • 单次注射失败后可考虑重复注射,不增加并发症风险。

局限性

  • 单中心回顾性研究,样本量小(8例患者,16次操作),为初步经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the clinical outcome of US-guided percutaneous thrombin injection in the treatment of non-femoral artery pseudoaneurysms (NFAP).

MATERIALS AND METHODS: Among all pseudoaneurysms treated in our institution, we retrospectively collected NFAP embolized with percutaneous thrombin injections from January 1, 2015, to December 31, 2021. The embolization was prompted for an ongoing antiaggregating/anticoagulation therapy, NFAP optimal US visibility, or high surgery-related risks. Causes, location, size and neck of NFAP, complications, number of repeated treatments, clinical success and patients clinical conditions at discharge were annotated. The endpoint for clinical success was the resolution of NFAP at postprocedural imaging, with no resort to surgery.

RESULTS: Eight consecutive patients (5 females, median age 73 years, range 46-84) underwent 16 procedures. Arterial damage was due to catheterization (3), CVC mispositioning (2), trauma, hemorrhagic diathesis and endoprosthesis endoleak. We treated humeral (2), subclavian (2), thyrocervical, anterior tibial, radial and pancreaticoduodenal arteries. Median pseudoaneurysm size was 530 mm2 (range 32-2400 mm2), with a thin (7/8) or non-visible (1/8) neck. No complications occurred. Clinical success was obtained in 7/8 patients (88%), with a single treatment in 4, multiple in 3 cases (4 embolizations, 3 and 2, respectively). One patient underwent surgical suture after the second failed attempt of percutaneous embolization. Seven patients were discharged in good clinical conditions; one died during hospitalization, due to the worsening of the underlying cardiac disease.

CONCLUSIONS: Percutaneous US-guided thrombin injection to treat NFAP is feasible in selected cases, with rare complications. Clinical success is often reached, also by repeated injections.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Muglia, Marra, Dulcetta, et al. US-guided percutaneous thrombin injection to treat non-femoral artery pseudoaneurysms: preliminary experience and review of the literature. Radiol Med. 2022. PMID: 36525178. doi:10.1007/s11547-022-01576-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。